Apexigen Raises $73 Million In Series B And Series C Financings

Tags:   Series C   Series B   Phase 2   Immuno-Oncology   Financing  

-- Proceeds to Support Ongoing Phase 2 Clinical Trials of Immuno-oncology Therapeutic APX005M and the Discovery and Development of a Pipeline of Novel Therapies --

SAN CARLOS, Calif., Aug. 8, 2018 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million.

The $15 million Series B financing was led by Decheng Capital and the recent $58 million Series C financing was led by 3E Bioventures Capital, Virtus Inspire Ventures, and SV Tech Ventures.  As a result of these financings, Apexigen's Board of Directors was expanded to include Dan Zabrowski, Ph.D. of Decheng Capital, and Karen Liu, Ph.D. of 3E Bioventures Capital.

---

---

Apexigen intends to use these proceeds to advance the clinical development of its lead immuno-oncology (I-O) therapeutic APX005M, a monoclonal antibody targeting CD40. Currently, APX005M is in multiple Phase 2 clinical trials to treat different types of cancers. The proceeds will also be used to discover and develop Apexigen's broader pipeline of therapies.

"Completing these financings puts Apexigen on a new trajectory for growth. We now have the resources to both execute our clinical development strategy for APX005M and accelerate building our pipeline of novel therapeutics based on our proprietary product discovery platform APXiMABTM," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "For APX005M, we are conducting a robust clinical program with 8 ongoing clinical trials, as we believe CD40 activation by APX005M will become a key component in several new I-O therapeutic regimens for treating cancer patients. Looking ahead, we will use our powerful discovery research engine to accelerate generation of new I-O therapeutics."

About APX005MAPX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as melanoma, non-small cell lung cancer, pancreatic cancer and renal cell carcinoma in various combinations with immunotherapy, chemotherapy or radiation therapy.

About ApexigenApexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient's immune system to combat and eradicate cancer. APX005M and the Company's additional preclinical programs were discovered using APXiMABTM, Apexigen's proprietary product discovery platform. This platform has enabled the Company and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product candidates discovered using APXiMABTM are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.

Apexigen Contact:Mark NevinsVice President, Business Development650-931-6236mnevins@apexigen.com

SOURCE Apexigen, Inc.

http://www.apexigen.com

More news releases in similar topics

You just read:

News provided by

Aug 08, 2018, 06:00 ET

Share this article

Share this article